Laurus Labs (LAURUSLABS) Aktievy
Laurus Labs Limited, tillsammans med sina dotterbolag, tillverkar och säljer läkemedel och aktiva farmaceutiska ingredienser (API) i Indien och internationellt. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 0/6 |
| Framtida tillväxt | 3/6 |
| Tidigare resultat | 4/6 |
| Finansiell hälsa | 5/6 |
| Utdelningar | 2/6 |
LAURUSLABS Community Fair Values
Create NarrativeSee what 17 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Laurus Labs Limited Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | ₹1,343.50 |
| 52 veckors högsta | ₹1,373.90 |
| 52 veckors lägsta | ₹585.90 |
| Beta | 0.35 |
| 1 månads förändring | 22.57% |
| 3 månaders förändring | 31.84% |
| 1 års förändring | 126.45% |
| 3 års förändring | 301.22% |
| 5 års förändring | 157.45% |
| Förändring sedan börsintroduktionen | 1,298.31% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Apr 30
LAURUSLABS: Upcoming Dividend Decision And Stable Assumptions Will Support Future Upside
Analysts have kept the Laurus Labs fair value estimate unchanged at ₹1,270, with small tweaks to revenue growth, profit margin and P/E assumptions. These reflect updated models rather than a shift in overall conviction.Uppdatering av berättelse • Apr 15
LAURUSLABS: Stronger Fundamentals And Upcoming Board Decisions Will Support Upside
Analysts have slightly reduced the Laurus Labs fair value estimate to ₹1,270 from ₹1,280 after updating assumptions on revenue growth, margins, and future P/E, while keeping the overall risk profile unchanged. Analyst Commentary Recent Street research on a different company, Laureate Education, still gives you a sense of how bullish analysts may think when they see improving fundamentals, supportive macro factors, or cleaner execution.Recent updates
Uppdatering av berättelse • Apr 30
LAURUSLABS: Upcoming Dividend Decision And Stable Assumptions Will Support Future Upside
Analysts have kept the Laurus Labs fair value estimate unchanged at ₹1,270, with small tweaks to revenue growth, profit margin and P/E assumptions. These reflect updated models rather than a shift in overall conviction.Uppdatering av berättelse • Apr 15
LAURUSLABS: Stronger Fundamentals And Upcoming Board Decisions Will Support Upside
Analysts have slightly reduced the Laurus Labs fair value estimate to ₹1,270 from ₹1,280 after updating assumptions on revenue growth, margins, and future P/E, while keeping the overall risk profile unchanged. Analyst Commentary Recent Street research on a different company, Laureate Education, still gives you a sense of how bullish analysts may think when they see improving fundamentals, supportive macro factors, or cleaner execution.
Uppdatering av berättelse • Apr 01
LAURUSLABS: Currency And Execution Uncertainties Will Likely Cap Margin Upside
Analysts have made a small upward tweak to the Laurus Labs fair value estimate, with the price target moving from ₹540.28 to ₹543.09. This reflects updated assumptions on revenue growth and profitability.Uppdatering av berättelse • Mar 18
LAURUSLABS: Higher Margin Assumptions Will Likely Struggle Against Execution Risks
Narrative Update on Laurus Labs The updated analyst price target for Laurus Labs moves from about ₹330 to roughly ₹540. Analysts point to revised assumptions for margins and future P/E, along with broadly steady growth expectations, as key drivers of the change.Uppdatering av berättelse • Mar 04
LAURUSLABS: Steady Fair Value And Solid Fundamentals Will Support Upside
Analysts have kept their price target for Laurus Labs steady at ₹1,280, reflecting small adjustments to assumptions on discount rate, revenue growth, profit margin and future P/E. These changes are consistent with recent Street research, where targets shifted within a relatively tight range and analysts cited solid fundamentals alongside mixed near term signals.
Uppdatering av berättelse • Feb 18
LAURUSLABS: Future Returns Will Rely On Confidence In Elevated P E Assumptions
Narrative Update: Laurus Labs Analyst Price Target Analysts have maintained their Laurus Labs price target at ₹913.47, citing largely unchanged assumptions around revenue, profit margins, discount rate, and forward P/E as the basis for keeping fair value steady. Analyst Commentary Analysts covering Laurus Labs are using a similar playbook to recent work on other education and healthcare names, where price targets are adjusted mainly on valuation inputs rather than big changes in growth assumptions.Uppdatering av berättelse • Feb 03
LAURUSLABS: Future Returns Will Depend On Confidence In Rich P E Assumptions
Analysts have lifted their fair value estimate for Laurus Labs from ₹863.13 to ₹913.47, citing slightly higher assumptions for revenue growth, profit margins and future P/E multiples, consistent with recent upward target revisions seen in related Street research. Analyst Commentary Bullish analysts point to the higher fair value estimate of ₹913.47 as support for a more constructive view on Laurus Labs, even though inputs are only slightly adjusted.Analysartikel • Jan 28
Results: Laurus Labs Limited Beat Earnings Expectations And Analysts Now Have New Forecasts
Laurus Labs Limited ( NSE:LAURUSLABS ) just released its quarterly report and things are looking bullish. It was...Analysartikel • Jan 25
Laurus Labs Limited's (NSE:LAURUSLABS) Popularity With Investors Is Under Threat From Overpricing
With a price-to-earnings (or "P/E") ratio of 65.1x Laurus Labs Limited ( NSE:LAURUSLABS ) may be sending very bearish...Uppdatering av berättelse • Jan 20
LAURUSLABS: Future Returns Will Depend On Rich P E Assumptions Holding
Analysts have lifted their price target for Laurus Labs to ₹863 from about ₹822, reflecting updated assumptions on fair value, profit margins, and future P/E multiples. Analyst Commentary Bullish Takeaways Bullish analysts view the higher price target as a sign that current assumptions on Laurus Labs' fair value leave room for upside if the company executes consistently on profitability.Uppdatering av berättelse • Jan 06
LAURUSLABS: Interim Dividend And Higher P E Multiple Will Support Upside
Analysts have raised their price target on Laurus Labs from ₹1,025 to ₹1,280, citing updated assumptions for revenue growth, profit margins, and a higher future P/E multiple. What's in the News The Board of Directors approved an interim dividend of ₹0.80 per equity share of face value ₹2 for the 2025-26 financial year at the meeting held on October 23, 2025 (company filing).Uppdatering av berättelse • Dec 21
LAURUSLABS: Interim Dividend May Not Offset Softer Margins Ahead
Analysts have moderately raised their price target on Laurus Labs from ₹303.09 to ₹330.21, citing a slightly higher justified valuation multiple that more than offsets their marginally softer assumptions on revenue growth and profit margins. What's in the News The Board approved an interim dividend of INR 0.80 per equity share (40 percent of the face value of INR 2) for FY 2025-26, signaling confidence in cash flows and shareholder returns (company filing).Uppdatering av berättelse • Dec 07
LAURUSLABS: Future Returns Will Likely Hinge On Managing Execution Risks
Analysts have modestly increased their price target for Laurus Labs while maintaining fair value at ₹821.93, citing expectations of sustained earnings growth supported by a solid balance sheet, margin expansion, and revenue momentum from new market opportunities. Analyst Commentary Street research on comparable growth stories in the education and healthcare sectors highlights themes that are directly relevant for Laurus Labs, particularly around how markets price in multi year earnings expansion, balance sheet strength, and scalability in new markets.Uppdatering av berättelse • Nov 23
LAURUSLABS: Future Revenue Upside May Be Limited By Execution Risks
Analysts have raised their price target for Laurus Labs slightly, from ₹815.86 to ₹821.93. They cite expectations of stronger revenue growth supported by a robust balance sheet and expanding opportunities in new markets.Uppdatering av berättelse • Nov 04
LAURUSLABS: Margin Pressures From Rising Input Costs Will Weigh On Earnings
Analysts have raised their fair value price target for Laurus Labs from ₹724.14 to ₹815.86. They cite increased profitability outlook and sustained margin growth as key drivers for the revision.Analysartikel • Oct 30
Laurus Labs' (NSE:LAURUSLABS) Dividend Will Be ₹0.80
Laurus Labs Limited ( NSE:LAURUSLABS ) will pay a dividend of ₹0.80 on the 22nd of November. Even though the dividend...Uppdatering av berättelse • Oct 21
Analysts Cite Growth Momentum and Strong Balance Sheet in Raising Laurus Labs Valuation Estimates
Analysts have raised their fair value estimate for Laurus Labs from ₹694.85 to ₹724.14. They cite continued revenue growth momentum and a strong balance sheet as key drivers for this upward revision.Analysartikel • Oct 19
With Laurus Labs Limited (NSE:LAURUSLABS) It Looks Like You'll Get What You Pay For
Laurus Labs Limited's ( NSE:LAURUSLABS ) price-to-sales (or "P/S") ratio of 8.2x may look like a poor investment...Analysartikel • Aug 31
Laurus Labs (NSE:LAURUSLABS) Seems To Use Debt Quite Sensibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysartikel • Jul 20
Revenues Tell The Story For Laurus Labs Limited (NSE:LAURUSLABS) As Its Stock Soars 28%
The Laurus Labs Limited ( NSE:LAURUSLABS ) share price has done very well over the last month, posting an excellent...Analysartikel • Jun 11
Investors Shouldn't Be Too Comfortable With Laurus Labs' (NSE:LAURUSLABS) Earnings
Unsurprisingly, Laurus Labs Limited's ( NSE:LAURUSLABS ) stock price was strong on the back of its healthy earnings...
Ny berättelse • Jan 26
CDMO Expansion May Impact Near-Term Margins But Pave Way For Future Revenue Streams
Heavy investment in CDMO and microbial precision initiatives may lead to revenue delays and short-term margin compression due to underutilized assets.Aktieägarnas avkastning
| LAURUSLABS | IN Pharmaceuticals | IN Marknad | |
|---|---|---|---|
| 7D | 1.5% | 1.5% | -0.2% |
| 1Y | 126.4% | 11.3% | 0.02% |
Avkastning vs industri: LAURUSLABS översteg Indian Pharmaceuticals branschen som gav 11.3 % under det senaste året.
Avkastning vs Marknaden: LAURUSLABS översteg Indian marknaden som gav 0 % under det senaste året.
Prisvolatilitet
| LAURUSLABS volatility | |
|---|---|
| LAURUSLABS Average Weekly Movement | 4.9% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.8% |
Stabil aktiekurs: LAURUSLABS har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för Indian.
Volatilitet över tid: LAURUSLABS s veckovolatilitet ( 5% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2005 | 6,167 | Satyanarayana Chava | www.lauruslabs.com |
Laurus Labs Limited, tillsammans med sina dotterbolag, tillverkar och säljer läkemedel och aktiva farmaceutiska ingredienser (API) i Indien och internationellt. Företaget erbjuder generiska API:er för avancerade mellanprodukter inom terapiområdena antiretrovirala läkemedel (ARV), antidiabetika, hjärt/kärl, antiastma, oftalmologi, onkologi, gastroenterologi och hepatit C. Företaget tillhandahåller också orala fasta beredningar för ARV, antidiabetika, hjärta/kärl och PPI. Dessutom erbjuder företaget tjänster inom kontraktsutveckling och kontraktstillverkning samt bioteknologitjänster som används i produkter inom områdena kosttillskott, nutraceuticals, alternativa livsmedelsproteiner och cosmeceuticals.
Laurus Labs Limited Sammanfattning av grunderna
| LAURUSLABS grundläggande statistik | |
|---|---|
| Börsvärde | ₹729.35b |
| Vinst(TTM) | ₹8.89b |
| Intäkter(TTM) | ₹68.13b |
81.6x
P/E-förhållande10.6x
P/S-förhållandeÄr LAURUSLABS övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| LAURUSLABS resultaträkning (TTM) | |
|---|---|
| Intäkter | ₹68.13b |
| Kostnad för intäkter | ₹26.95b |
| Bruttovinst | ₹41.17b |
| Övriga kostnader | ₹32.29b |
| Intäkter | ₹8.89b |
Senast redovisade vinst
Mar 31, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | 16.46 |
| Bruttomarginal | 60.44% |
| Nettovinstmarginal | 13.05% |
| Skuld/egenkapitalförhållande | 44.1% |
Hur har LAURUSLABS utvecklats på lång sikt?
Se historisk utveckling och jämförelseUtdelningar
0.2%
Aktuell utdelningsavkastning12%
UtbetalningskvotGer LAURUSLABS en tillförlitlig utdelning?
Se LAURUSLABS utdelningshistorik och jämförelsetal| Laurus Labs datum för utdelning | |
|---|---|
| Ex utdelningsdag | May 08 2026 |
| Utbetalningsdag för utdelning | May 30 2026 |
| Dagar till Ex-utdelning | 15 days |
| Dagar till utdelningsdag | 7 days |
Ger LAURUSLABS en tillförlitlig utdelning?
Se LAURUSLABS utdelningshistorik och jämförelsetalFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/22 15:18 |
| Aktiekurs vid dagens slut | 2026/05/22 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2026/03/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Laurus Labs Limited bevakas av 22 analytiker. 14 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Ashwin Mehta | Ambit Capital |
| null null | Antique Stockbroking Ltd. |